Reference health
Review: A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality
216/216 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
20 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 216 checked references that resolve
resolves10.1192/bjp.168.1.57
Enhancement of the Prolactin Response to d-Fenfluramine in Drug-Naive Schizophrenic Patients
resolves10.1177/070674379003500512
Depression Dexamethasone Nonsuppression and Negative Symptoms in Schizophrenia
resolves10.1016/0165-1781(82)90026-9
Situational reactivity of autonomic functions in schizophrenic patients
resolves10.1111/j.1600-0447.1988.tb06405.x
Dexamethasone suppression test, schizophrenia and movement disorder
resolves10.1016/0165-1781(89)90173-X
Dexamethasone suppression test in positive and negative schizophrenia
resolves10.1016/0306-4530(86)90055-7
Associations among dexamethasone non-suppression and TRH-induced hormonal responses: increased specificity for melancholia
resolves10.1176/ajp.144.7.873
CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia
resolves10.1007/BF00380966
Dexamethasone suppression and multiple hormonal responses (TSH, prolactin and growth hormone) to TRH in some psychiatric disorders
resolves10.1016/0006-3223(85)90103-9
The dexamethasone suppression test in depression, in schizophrenia, and during experimental stress
resolves10.1007/s10286-005-0290-7
Paraventricular nucleus, stress response, and cardiovascular disease
resolves10.1192/bjp.145.4.372
The Limited Utility of the Dexamethasone Suppression Test for the Diagnostic Process in Psychiatry
resolves10.1016/j.schres.2004.07.007
Diurnal cortisol in schizophrenia patients with childhood trauma
resolves10.1016/0024-3205(92)90563-5
The effects of metabolic stress on plasma progesterone in healthy volunteers and schizophrenic patients
resolves10.1001/archpsyc.1993.01820190043005
Effects of Metabolic Perturbation on Plasma Homovanillic Acid in Schizophrenia
resolves10.1016/0165-1781(88)90050-9
Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers
resolves10.1016/j.psyneuen.2009.01.002
Cortisol response to a psychosocial stressor in schizophrenia: Blunted, delayed, or normal?
resolves10.2165/00023210-200923070-00004
Cardiovascular Abnormalities in Patients with Major Depressive Disorder
resolves10.1016/j.schres.2007.11.009
Effects of acute metabolic stress on the dopaminergic and pituitary–adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls
resolves10.1016/0165-1781(84)90028-3
Endocrine effects of the cold pressor test: Relationships to subjective pain appraisal and coping
resolves10.1176/appi.ajp.159.7.1080
Obstetric Complications and Schizophrenia: Historical and Meta-Analytic Review
resolves10.1192/bjp.148.1.58
Raised Plasma Cortisol Concentrations a Feature of Drug-Free Psychotics and not Specific for Depression
resolves10.1007/s00213-005-0279-x
The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects
resolves10.1093/schbul/sbn151
Physical Manifestations of Neurodevelopmental Disruption: Are Minor Physical Anomalies Part of the Syndrome of Schizophrenia?
resolves10.1016/0165-1781(86)90026-0
Clinical utility of the dexamethasone suppression test assessed by plasma and salivary cortisol determinations
resolves10.1192/bjp.142.5.498
Dexamethasone Suppression Test in Depression and other Psychiatric Illness
resolves10.1176/ajp.149.8.1033
Hypothalamic-pituitary-adrenal axis hyperactivity and psychosis: recovery during an 8-year follow-up
resolves10.1016/j.psyneuen.2008.02.005
HPA-axis hyperactivity and mortality in psychotic depressive disorder: Preliminary findings
resolves10.1016/j.psychres.2005.08.009
Hyperactivity of the hypothalamic–pituitary–adrenal axis and mortality in major depressive disorder
resolves10.1007/BF00449907
Baseline neuroendocrine function and diagnostic stability among patients with a nonmanic psychosis
resolves10.1016/0024-3205(89)90339-1
Persistence of cyclicity of the plasma dopamine metabolite. Homovanillic acid, in neuroleptic treated schizophrenic patients
resolves10.1177/0269881108097817
Association of HPA axis genes with suicidal behaviour in schizophrenia
resolves10.1176/ajp.139.11.1501
Abnormal dexamethasone suppression test results in chronic schizophrenic patients
resolves10.1001/archpsyc.1986.01800040075011
CSF Somatostatin and Abnormal Response to Dexamethasone Administration in Schizophrenic and Depressed Patients
resolves10.1016/S0278-5846(99)00098-6
Dopaminergic function and the cortisol response to dexamethasone in psychotic depression
resolves10.1016/S0306-4530(02)00047-1
Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests
resolves10.1176/ajp.155.7.979
Effect of Acute Metabolic Stress on Pituitary-Adrenal Axis Activation in Patients With Schizophrenia
resolves10.1016/j.psyneuen.2007.11.004
Diminished cortisol responses to psychosocial stress associated with lifetime adverse events
resolves10.1016/0022-3999(71)90050-X
Serum cortisol in chronic schizophrenia. A study of the diurnal rhythm in relation to psychiatric mental status
resolves10.1111/j.1440-1819.2009.01983.x
Autonomic nervous system activity and psychiatric severity in schizophrenia
resolves10.1016/j.psyneuen.2005.02.001
Psychological determinants of the cortisol stress response: the role of anticipatory cognitive appraisal
resolves10.1016/j.schres.2006.11.020
Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder
resolves10.1111/j.1600-0447.1993.tb03485.x
Negative symptoms of schizophrenia and the dexamethasone suppression test
resolves10.1016/0306-4530(85)90012-5
Increased CSF cortisol levels after neuroleptic treatment in schizophrenia
resolves10.2174/157339907782330021
A Review of the Evidence for a Neuroendocrine Link Between Stress, Depression and Diabetes Mellitus
resolves10.1176/ajp.150.4.653
Association of nonsuppression of cortisol on the DST with primary polydipsia in chronic schizophrenia
resolves10.1038/sj.npp.1301282
Neuroendocrine Responses to a Cold Pressor Stimulus in Polydipsic Hyponatremic and in Matched Schizophrenic Patients
resolves10.1016/S0006-3223(96)89256-0
Dexamethasone nonsuppression and short rapid eye movement latency in schizophrenia: Markers of an affective diathesis?
resolves10.1016/j.cpr.2007.05.005
Depression and coronary heart disease: A review of the epidemiological evidence, explanatory mechanisms and management approaches
resolves10.1196/annals.1314.042
Negative Correlation between Negative Symptoms of Schizophrenia and Testosterone Levels
resolves10.1210/endo.136.3.7867583
Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect.
resolves10.1210/jcem-54-6-1262
The Mean 1300-1600 h Plasma Cortisol Concentration as a Diagnostic Test for Hypercortisolism*
resolves10.1016/0006-3223(90)90471-D
Comparisons of plasma and salivary cortisol determinations for the diagnostic efficacy of the dexamethasone suppression test
resolves10.1016/S0306-4530(99)00035-9
The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders
resolves10.1016/j.psyneuen.2008.03.008
The link between childhood trauma and depression: Insights from HPA axis studies in humans
resolves10.1136/bmj.318.7196.1460
Evidence based cardiology: Psychosocial factors in the aetiology and prognosis of coronary heart disease: systematic review of prospective cohort studies
resolves10.1176/ajp.142.1.127
The dexamethasone suppression test in newly hospitalized schizophrenic patients
resolves10.1016/0022-3956(94)90017-5
The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders
resolves10.1111/j.1600-0447.1987.tb02844.x
Dexamethasone suppression test in severe schizophrenic illness: Effects of plasma dexamethasone and caffeine levels
resolves10.1159/000118297
The Dexamethasone Suppression Test in Affective Illnesses and Schizophrenia: Relationship with Psychotic Symptoms
resolves10.3109/15622970109039981
Meuroendocrine Effects of a Short-Term Osmotic Stimulus in Patients with Chronic Schizophrenia
resolves10.1016/0006-3223(91)90233-C
The MCPP challenge test in schizophrenia: Hormonal and behavioral responses
resolves10.1016/S0920-9964(98)00066-8
Blunted cortisol response to a psychosocial stressor in schizophrenia
resolves10.1016/j.jad.2008.10.015
HPA axis hyperactivity and attempted suicide in young adult mood disorder inpatients
resolves10.1016/j.jad.2008.10.025
HPA axis hyperactivity and cardiovascular mortality in mood disorder inpatients
resolves10.1093/schbul/sbl058
A New Look at the Neural Diathesis Stress Model of Schizophrenia: The Primacy of Social-Evaluative and Uncontrollable Situations
resolves10.1111/j.1600-0447.1994.tb01491.x
Negative and depressive symptoms in suicidal schizophrenics
resolves10.1016/0006-3223(87)90216-2
Dexamethasone suppression test in schizophrenic patients: Report from India
resolves10.1016/j.neubiorev.2009.10.002
Allostatic load biomarkers of chronic stress and impact on health and cognition
resolves10.1016/j.psychres.2009.01.013
Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: Implications for altered one-carbon metabolism
resolves10.1016/S0278-5846(02)00208-7
The hypothalamic–pituitary–adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics
resolves10.1016/0022-3956(92)90002-6
Blunted acth response to hypoglycemic stress in depressed patients but not in patients with schizophrenia
resolves10.1176/ajp.156.6.837
Causal Relationship Between Stressful Life Events and the Onset of Major Depression
resolves10.1016/0165-1781(88)90025-X
Neuroendocrine dysfunction in schizophrenia: A familial perspective
resolves10.1016/0006-3223(88)90178-3
TRH test and DST in schizoaffective mania, mania, and schizophrenia
resolves10.1001/archpsyc.1993.01820200034004
m-Chlorophenylpiperazine Effects in Neuroleptic-Free Schizophrenic Patients
resolves10.3109/10253890902874913
Human models in acute and chronic stress: Assessing determinants of individual hypothalamus–pituitary–adrenal axis activity and reactivity
resolves10.1159/000026572
Pituitary-Adrenal and Parasympathetic Function in Chronic Schizophrenic Patients with Postoperative Ileus or Hypotension
resolves10.1159/000119372
Depressed Pituitary-Adrenal Response to Surgical Stress in Chronic Schizophrenic Patients
resolves10.1159/000063569
Schizophrenic Patients Who Develop Postoperative Confusion Have an Increased Norepinephrine and Cortisol Response to Surgery
resolves10.1016/j.coph.2009.08.007
Stress hormones: physiological stress and regulation of metabolism
resolves10.1016/0006-3223(95)00065-8
Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II
resolves10.1016/S0165-1781(01)00284-0
Effects of clozapine on sleep measures and sleep-associated changes in growth hormone and cortisol in patients with schizophrenia
resolves10.1016/0920-9964(88)90022-9
Neuroendocrine responses in chronic schizophreniaEvidence for serotonergic dysfunction
resolves10.1016/0893-133X(88)90007-3
The specificity of the dexamethasone suppression test in endogenous depressive patients
resolves10.1016/j.schres.2005.07.014
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III
resolves10.1111/j.1749-6632.2009.05331.x
Central role of the brain in stress and adaptation: Links to socioeconomic status, health, and disease
resolves10.1111/j.1600-0447.1989.tb03024.x
The dexamethasone suppression test and negative symptoms of schizophrenia
resolves10.1016/j.biopsych.2008.12.014
Cortisol Response to Stress in Female Youths Exposed to Childhood Maltreatment: Results of the Youth Mood Project
resolves10.1016/S0006-3223(96)00223-5
Plasma sialyltransferase levels in psychiatric disorders as a possible indicator of HPA axis function
resolves10.1097/01.yic.0000182118.57510.d1
A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan
resolves10.1016/S0924-977X(99)00040-1
Switch from neuroleptics to clozapine does not influence pituitary–gonadal axis hormone levels in male schizophrenic patients
resolves10.1097/00005053-198603000-00003
Urinary Free-Cortisol Levels in Posttraumatic Stress Disorder Patients
resolves10.1007/BF00442554
Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia
resolves10.1016/S0893-133X(00)00201-3
The Blunted Plasma Cortisol Response to Apomorphine and Its Relationship to Treatment Response in Patients with Schizophrenia
resolves10.1016/j.biopsych.2008.11.029
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
resolves10.1016/0920-9964(90)90017-2
Depression, negative and positive symptoms, and the DST in schizophrenia
resolves10.1016/j.biopsych.2006.08.043
The Relations Among Putative Biorisk Markers in Schizotypal Adolescents: Minor Physical Anomalies, Movement Abnormalities, and Salivary Cortisol
resolves10.1007/BF00515912
The dexamethasone suppression test in depressive and schizophrenic patients under controlled treatment conditions
resolves10.2174/157340008786576571
Hypothalamus-Pituitary-Adrenal (HPA) Axis and Metabolic Abnormalities in First-Episode Psychosis
resolves10.1016/j.schres.2009.08.013
Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: The role of stress and of antipsychotic treatment
resolves10.1016/0920-9964(92)90077-I
Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics
resolves10.1159/000119137
Seasonal Variation in the Dexamethasone Suppression Test: A Longitudinal Study in Chronic Schizophrenics and in Healthy Subjects
resolves10.1016/S0006-3223(98)00270-4
Prolactin hyperresponsiveness to d-fenfluramine in drug-free schizophrenic patients: a placebo-controlled study
resolves10.1016/S0006-3223(98)00174-7
Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients
resolves10.1016/j.psychres.2004.04.001
Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women
resolves10.1176/ajp.141.2.250
The dexamethasone suppression test in residual schizophrenia with depression
resolves10.1126/science.6334362
Elevated Concentrations of CSF Corticotropin-Releasing Factor-Like Immunoreactivity in Depressed Patients
resolves10.1159/000118709
Prolactin and Growth Hormone Responses to Growth Hormone-Releasing Hormone in Acute Schizophrenia
resolves10.1016/0006-3223(91)90052-N
Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients
resolves10.1016/S0165-1781(98)00012-2
Cerebrospinal fluid prostaglandins and corticotropin releasing factor in schizophrenics and controls: relationship to sleep architecture
resolves10.1016/0165-1781(87)90105-3
Decreased beta-adrenergic receptors in the leukocytes of depressed patients
resolves10.1016/0165-1781(92)90064-A
Monoamine oxidase and cortisol response in depression and schizophrenia
resolves10.1055/s-2007-1017073
Dexamethasone Suppression Test and Depressive Symptoms in Schizophrenics and Endogenous Depressed Patients
resolves10.1016/j.biopsych.2004.11.017
Hypothalamus-pituitary-adrenal system regulation and suicidal behavior in depression
resolves10.2337/diacare.27.3.813
Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabetes
resolves10.1159/000119354
Platelet 5-HT Levels and Hypothalamic-Pituitary-Adrenal Axis Activity in Schizophrenic Patients with Positive and Negative Symptoms
resolves10.1016/S0924-9338(01)00602-2
Dexamethasone suppression test and suicide attempts in schizophrenic patients
resolves10.1159/000103868
Changes in Neuroendocrine and Metabolic Hormones Induced by Atypical Antipsychotics in Normal-Weight Patients with Schizophrenia
resolves10.1016/j.biopsych.2007.09.024
Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review
resolves10.1016/j.psyneuen.2009.02.016
Stress regulation in the central nervous system: evidence from structural and functional neuroimaging studies in human populations - 2008 Curt Richter Award Winner
resolves10.1176/appi.ajp.160.9.1554
When Not Enough Is Too Much: The Role of Insufficient Glucocorticoid Signaling in the Pathophysiology of Stress-Related Disorders
resolves10.1016/0165-1781(95)02525-2
Circadian rhythm of vital signs, norepinephrine, epinephrine, thyroid hormones, and cortisol in schizophrenia
resolves10.1111/j.1600-0447.2005.00634.x
Childhood trauma, psychosis and schizophrenia: a literature review with theoretical and clinical implications
resolves10.1210/jc.2009-2112
Elevated Fasting Plasma Cortisol Is Associated with Ischemic Heart Disease and Its Risk Factors in People with Type 2 Diabetes: The Edinburgh Type 2 Diabetes Study
resolves10.1016/j.euroneuro.2006.09.001
State and trait related predictors of serum cortisol to DHEA(S) molar ratios and hormone concentrations in schizophrenia patients
resolves10.1016/j.euroneuro.2003.09.003
Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients
resolves10.1046/j.1365-2826.1996.04441.x
Patterns of ACTH Secretagog Secretion in Response to Psychological Stimuli
resolves10.1192/bjp.141.5.471
The Dexamethasone Suppression Test as a Discriminator among Subtypes of Psychotic Patients
resolves10.1176/ajp.143.11.1393
The corticotropin-releasing hormone stimulation test in chronic schizophrenia
resolves10.1176/appi.ajp.160.2.284
Impaired Fasting Glucose Tolerance in First-Episode, Drug-Naive Patients With Schizophrenia
resolves10.1016/j.lfs.2003.08.044
The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia
resolves10.1016/j.psyneuen.2003.08.011
Evidence of basal pituitary–adrenal overactivity in first episode, drug naïve patients with schizophrenia
resolves10.1016/0165-0327(92)90022-X
Seasonal variations of the dexamethasone suppression test in depression compared with schizophrenia: a gender effect
resolves10.1007/BF00381358
The dexamethasone suppression test and thyroid stimulating hormone response to TRH in RDC schizoaffective patients
resolves10.1001/archpsyc.1980.01780200015001
Hypothalamic-Pituitary-Adrenal Axis Activity in Depressive Illness
resolves10.1016/0006-3223(88)90166-7
The effect of diagnosis and age on the DST: A metaanalytic approach
resolves10.1016/S0920-9964(01)00367-X
Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia
resolves10.1016/0006-3223(86)90123-X
Dexamethasone suppression test and noradrenergic function in affective and schizophrenic disorders
resolves10.1111/j.1464-5491.2007.02092.x
Impaired glucose tolerance in first‐episode drug‐naïve patients with schizophrenia
resolves10.1007/BF02190088
Nocturnal melatonin and cortisol secretion in newly admitted psychiatric inpatients
resolves10.1016/0022-3999(96)00095-5
Stress, social support and health-related behavior: A study of smoking, alcohol consumption and physical exercise
resolves10.1001/archpsyc.1984.01790140047006
Pretreatment DST and Hypothalamic-Pituitary-Adrenocortical Function in Depressed Patients and Comparison Groups
resolves10.1016/j.schres.2004.03.005
Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology
resolves10.1016/0006-3223(96)00205-3
Relationship between DST nonsuppression and shortened REM latency in schizophrenia
resolves10.1016/0006-3223(91)90353-N
Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome
resolves10.1016/0006-3223(89)90251-5
Positive and negative symptoms in schizophrenia and the dexamethasone suppression test
resolves10.1176/ajp.140.3.309
Neuroendocrine dysfunction in schizophreniform disorder: correlation with six-month clinical outcome
resolves10.1038/sj.ijo.0801840
Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia
resolves10.1016/S0022-3999(02)00429-4
Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress
resolves10.1001/archpsyc.1991.01810280064009
Circadian and Sleep-Related Endocrine Rhythms in Schizophrenia
resolves10.1176/appi.ajp.2007.07020233
Insulin and Insulin-Like Growth Factor-1 Abnormalities in Antipsychotic-Naive Schizophrenia
resolves10.1016/j.schres.2010.01.033
Effect of antipsychotic treatment on Insulin-like Growth Factor-1 and cortisol in schizophrenia: A longitudinal study
resolves10.1159/000119439
The Dexamethasone Suppression Test in a Group of Research Diagnostic Criteria Schizoaffective Depressed Men
resolves10.1146/annurev.clinpsy.4.022007.141248
Stress and the Hypothalamic Pituitary Adrenal Axis in the Developmental Course of Schizophrenia
resolves10.1016/j.psyneuen.2004.11.003
Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release
resolves10.1136/bmj.290.6462.99
Selective increase in plasma luteinising hormone concentrations in drug free young men with mania.
resolves10.1677/joe.0.1440425
Effects of neuroleptic treatment on cortisol and 3-methoxy-4-hydroxyphenylethyl glycol levels in blood
resolves10.1111/j.1600-0447.1986.tb10600.x
Dexamethasone suppression test in schizophrenic patients before and during neuroleptic treatment
resolves10.1007/BF02190280
Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients
resolves10.1016/S0006-3223(97)00323-5
A Single Administration of Dehydroepiandrosterone Does Not Enhance Memory Performance in Young Healthy Adults, but Immediately Reduces Cortisol Levels
resolves10.1016/0006-3223(86)90164-2
Endogenous opioid regulation of hypothalamo-pituitary-adrenal axis activity in schizophrenia
resolves10.1016/0165-1781(89)90032-2
Specificity of plasma HVA response to dexamethasone in psychotic depression
resolves10.1016/S0278-5846(01)00311-6
Different neuroendocrine profiles of remitted and nonremitted schizophrenic patients
resolves10.1177/070674379003500204
The Incidence of Abnormal Dexamethasone Suppression in Schizophrenia: A Review and a Meta-Analytic Comparison with the Incidence in Normal Controls
resolves10.1159/000098367
Increased Levels of Nitric Oxide, Cortisol and Adrenomedullin in Patients with Chronic Schizophrenia
resolves10.1038/sj.npp.1300756
Cortisol and Cytokines in Chronic and Treatment-Resistant Patients with Schizophrenia: Association with Psychopathology and Response to Antipsychotics
resolves10.1016/0006-3223(87)90086-2
Dexamethasone suppression test and urinary MHPG · SO4 determination in depressive disorders
The 20 references without a DOI — listed, not checked
no DOI — not checkedatypb21
no DOI — not checkedatypb23
no DOI — not checkedatypb30
no DOI — not checkedatypb48
no DOI — not checkedatypb64
no DOI — not checkedatypb81
no DOI — not checkedatypb85
no DOI — not checkedatypb87
no DOI — not checkedatypb92
no DOI — not checkedatypb99
no DOI — not checkedatypb144
no DOI — not checkedatypb153
no DOI — not checkedatypb163
no DOI — not checkedatypb175
no DOI — not checkedatypb176
no DOI — not checkedatypb193
no DOI — not checkedatypb196
no DOI — not checkedSterling P. and Eyer J. ( 1988) Allostasis: a new paradigm to explain arousal pathology . In: Fisher S and Reason J (eds) Handbook of Life Stress, Cognition and Health . New York: John Wiley & Sons , 629.
no DOI — not checkedatypb206
no DOI — not checkedatypb213
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1177/1359786810385491"><img src="https://citestamp.com/citestamped/10.1177/1359786810385491/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1177/1359786810385491)